Behavioral mediation of the relationship between psychosocial factors and HIV disease progression

Psychosomatic Medicine

Volumn 70, Issue 5, 2008, Pages 569-574

  Gore Felton, Cheryl ^a   Koopman, Cheryl ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Behavioral mechanisms; Disease progression; HIV; Psychosocial

Indexed keywords

BEHAVIOR CHANGE; COPING BEHAVIOR; DEPRESSION; DISEASE COURSE; EXERCISE; HABIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILLNESS BEHAVIOR; MORBIDITY; MORTALITY; MOTIVATION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; SEXUAL BEHAVIOR; SOCIAL ASPECT; SOCIAL SUPPORT; STRESS; SUBSTANCE ABUSE; ADAPTIVE BEHAVIOR; ADDICTION; BEHAVIOR THERAPY; DISEASE MANAGEMENT; HEALTH BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; LIFE EVENT; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; UNSAFE SEX; VIROLOGY;

STREET DRUG;

ADAPTATION, PSYCHOLOGICAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BEHAVIOR THERAPY; DEPRESSION; DISEASE MANAGEMENT; DISEASE PROGRESSION; HEALTH BEHAVIOR; HIV INFECTIONS; HIV-1; HUMANS; LIFE CHANGE EVENTS; MOTIVATION; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOCIAL SUPPORT; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; UNSAFE SEX;

EID: 50949115083     PISSN: 00333174     EISSN: 15347796     Source Type: Journal    
DOI: 10.1097/PSY.0b013e318177353e     Document Type: Review

References (80)

1. Beaudin CL, Chambre SM. HIV/AIDS as a chronic disease: emergence from the plague model. Am Behav Sci 1996;39:684-706.
2. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richaman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739
3. Markowitz M, Conant M, Hurley A, Schluger R, Duran M, Peterkin J, Chapman S, Patick A, Hendricks A, Yuen GJ, Hoskins W, Clendeninn N, Ho DD. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998;177:1533-1540
4. Moyle GJ, Youle M, Higgs C, Monaghan J, Prince W, Chapman S, Clendeninn N, Nelson MR. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J Clin Pharmacol 1998;38:726-743
5. Whetten K, Reif S, Whetten R, Murphy-McMillan L. Trauma, mental health, distrust and stigma among HIV positive persons: implications for effective care. Psychosom Med 2008;70:531-538
6. Sackett DL, Snow JC. The magnitude of compliance and noncompliance. In: Haynes RB, Taylor DW, Sackett DL, editors. Compliance in Health Care. Baltimore: Johns Hopkins University Press; 1979.
7. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDs 2003;17:169-177
8. Anastos K, Schneider MF, Gange SJ, Minkoff H, Greenblatt RM, Feldman J, Levine A, Delapenha R, Cohen M. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr 2005;39:537-544
9. Bouhnik AD, Preau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther 2005;10:53-61.
10. Ironson G, Friedman A, Klimas N, Antoni M, Fletcher MA, LaPerriere A, Simoneu J, Schneiderman N. Distress, denial, and low adherence to behavioral interventions predict faster disease progression in gay men infected with human immunodeficiency virus. Int J Behav Med 1994;1: 90-105.
11. Altice FL, Friedland GH. The era of adherence to HIV therapy. Ann Intern Med 1998;129:503-505
12. Crespo-Fierro M. Compliance/adherence and care management in HIV disease. J Assoc Nurses AIDS Care 1997;8:43-54.
13. Battaglioli-DeNero AM. Strategies for improving patient adherence to therapy and long-term patient outcomes. JANAC 2007;18:S17-22.
14. Cook JA, Grey D, Burke J, Cohen MH, Gurtman AC, Richardson JL, Wilson TE, Young MA, Hessol NA. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health 2004;94:1133-1140
15. Lima VD, Geller J, Bangsberg DR, Patterson TL, Daniel M, Kerr T, Montaner JSG, Hogg RS. The effects of adherence on the association between depressive symptoms and mortality among HIV infected individuals first initiating HAART. AIDS 2007;21:1175-1183
16. Centers for Disease Control and Prevention (CDC, 2006). AIDS surveillance-general epidemiology (through 2005). Available at http:// www.cdc.gov/hiv/resources/factsheets/idu.htm.
17. Petersen PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH Jr. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS 1990;4:869-873
18. Petersen PK, Gekker G, Chao CC, Schut R, Molitor TW, Balfour HH Jr. Cocaine potentiates HIV-1 replication in human peripheral blood mono-nuclear cell cocultures. Involvement of transforming growth factor-beta. J Immunol 1991;146:81-84
19. Mientjes GH, Miedema F, van Ameijden EJ, van den Hoek AA, Schellenkens PT, Roos MT, Coutinho RA. Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users. AIDS 1991;5:35-41.
20. Webber MP, Schoenbaum EE, Gourevitch MN, Buono D, Klein RS. A prospective study of HIV disease progression in female and male drug users. AIDS 1999;13:257-262
21. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. JAIDS 2001;27:251-259
22. Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, Myers HF, Longshore D. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav 2007;11:185-194
23. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002;16:767-774
24. Rompalo AM, Shah N, Marglick JB, Farzadegan H, Arnsten J, Schuman P, Rich JD, Gardner LI, Smith DK, Vlahov D. Evaluation of possible effects of continued drug use on HIV progression among women. Int J STD AIDS 2004;15:322-327
25. Crisp BR, Williams M, Timpson S, Ross MW. Medication compliance and satisfaction with treatment for HIV disease in a sample of African-American crack cocaine smokers. AIDS Behav 2004;8:199-206.
26. Mohammed H, Kieltyka L, Richardson-Alston G, Magnus M, Fawal H, Vermund SH, Rice J, Kissinger P. Adherence to HAART among HIV-infected persons in rural Louisiana. AIDS Patient Care STDS 2004;18: 289-296
27. Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, Stefaniak M. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance use. AIDS 2004;18:S19-S25.
28. Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P, Stone VE, Smith DK, Schoenbaum EE, HER Study Group. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 2002;12:2175-2182
29. Dingle GA, Oei TP. Is alcohol a cofactor of HIV and AIDS? Evidence from immunological and behavioral studies. Psych Bull 1997;122:56-71.
30. Samet JH, Horton NJ, Traphagen ET, Lyon SM, Freedberg KA. Alcohol consumption and HIV disease progression: are they related? Alcohol Clin Exp Res 2003;27:862-867
31. Parsons JT, Kutnick AH, Halkitis PN, Punzalan JC, Carbonari JP. Sexual risk behaviors and substance use among alcohol abusing HIV-positive men who have sex with men. J Psychoactive Drugs 2005;37:27-36.
32. Samet JH, Cheng DM, Libman H, Nunes DP, Alperen JK, Saitz R. Alcohol consumption and HIV disease progression. JAIDS 2007;46: 194-199
33. Miguez-Burbano MJ, Ashkin D, Rodriguez A, Duncan R, Pitchenik A, Quintero N, Flores M, Shor-Posner G. Increased risk of Pneumocystis carinii and community-acquired pneumonia with tobacco use in HIV disease. Int J Infect Dis 2005;9:208-217
34. Miguez-Burbano MJ, Brubano X, Ashkin D, Pitchenik A, Allan R, Pineda L, Rodriguez N, Shor-Posner G. Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy. Addiction Biol 2003;8:39-43.
35. Selwyn PA, Alcabes P, Hartel D, Buono D, Schoenbaum EE, Klein RS, Davenny K, Friedland GH. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992;327:1697-703. Erratum in N Engl J Med 1993;328:671.
36. Grulich AE, Olsen SJ, Luo K, Hendry O, Cunningham P, Cooper DA, Gao SJ, Chang Y, Moore PS, Kaldor JM. Kaposi's sarcoma-associated herpes virus: a sexually transmissible infection? J Acquir Immune Defic Syndr 1999;20:387-393
37. Blackard JT, Cohen DE, Mayer KH. Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin Inf Dis 2002;34:1108-1114
38. Blackard JT, Mayer KH. HIV superinfection in the era of increased sexual risk-taking. Sex Trans Dis 2004;31:201-204
39. Francis K. Physical activity in the prevention of cardiovascular disease. Phys Ther 1996;76:456-468 (Pubitemid 26152742)
40. Blair SN, Horton E, Leon AS, Lee IM, Drinkwater BL, Dishman RK, Mackey M, Kienholz ML. Physical activity, nutrition, and chronic disease. Med Sci Sports Exerc 1996;28:335-349
41. MacArthur RD, Sheldon DL, Birk TJ. Supervised exercise training improves cardiopulmonary fitness in HIV-infected persons. Med Sci Sports Exerc 1993;25:684-688
42. LaPerriere A, Fletcher MA, Antoni MH, Klimas N, Ironson G, Schneiderman N. Aerobic exercise training in an AIDS risk group. Int J Sports Med 1991;12:S52-S57.
43. LaPerriere A, Antoni MH, Schneiderman N, Ironson G, Klimas N, Caralis P, Fletcher MA. Exercise intervention attenuates emotional distress and natural killer cell decrements following notification of positive serologic status for HIV-1. Biofeedback Self Regul 1990;15:229-242
44. Evans WJ, Roubenoff R, Shevitz A. Exercise and the treatment of wasting: aging and human immunodeficiency virus infection. Semin Oncol 1998;25:112-122
45. Mustafa T, Sy FS, Macera CA, Thompson SJ, Jackson KL, Salassie A, Dean LL. Association between exercise and HIV disease progression in a cohort of homosexual men. Ann Epidemiol 1999;9:127-131
46. O'Brien K, Nixon S, Tynan AM, Glazier R. Effectiveness of aerobic exercise in adults living with HIV/AIDS: systematic review. Med Sci Sports Exerc 2004;36:1659-1666
47. Meade-D'Alisera P, Merriweather T, Wentland M, Fatal M, Ghafar M. Depression symptoms in women with urinary incontinence: a prospective study. Urol Nurs 2001;21:397-399
48. Komiti A, Judd F, Grech P, Mijch A, Hoy J, Williams B, Street A, Lloyd JH. Depression in people living with HIV/AIDS attending primary care and outpatient clinics. AIDS 2003;37:70-78
49. Leserman J. Role of stress, trauma, and depression in HIV disease progression. Psychosom Med 2008;70:539-545
50. Antoni MH, Cruess DG, Klimas N, Carrico AW, Maher K, Cruess S, Lechner SC, Kumar M, Lutgendorf S, Ironson G, Fletcher MA, Schneiderman N. Increases in a marker of immune system reconsti-tution are predated by decreases in 24-h urinary cortisol output and depressed mood during a 10-week stress management intervention in symptomatic HIV-infected men. J Psychosom Res 2005;58:3-13.
51. Moskowitz JT. Positive affect predicts lower risk of AIDS mortality. Psychosom Med 2003;65:620-626
52. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985;142:1259-1264
53. Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, Moore J. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA 2001;285:1460-1465
54. Gore-Felton C, Koopman C. Traumatic experiences: harbinger of risk behavior among HIV-positive adults. J Trauma Dissoc 2002;3:121-135
55. Evans DL, Leserman J, Perkins DO, Stern RA, Murphy C, Zheng B, Gettes D, Longmate JA, Silva SG, van der Horst CM, Hall CD, Folds JD, Golden RN, Petitto JM. Severe life stress as a predictor of early disease progression in HIV infection. Am J Psychiatry 1997;154:630-634
56. Lutgendorf SK, Antoni MH, Ironson G, Klimas N. Cognitive processing style, mood, and immune function following HIV seropositivity notification. Cognitive Ther Res 1997;21:157-184
57. Stewart KE, Cianfrini LR, Walker JF. Stress, social support and housing are related to health status among HIV-positive persons in the Deep South of the United States. AIDS Care 2005;17:350-358
58. Cole SW. Psychosocial influences on HIV-1 disease progression: neural, endocrine and virologic mechanisms. Psychosom Med 2008;70:562-568
59. Pillai R, Nair BS, Watson RR. AIDS, drugs of abuse and the immune system: a complex immunotoxicological network. Arch Toxicol 1991;65:609-617
60. Mugavero MJ, Pence BW, Whetten K, Leserman J, Swartz M, Stangl D, Thielman NM. Predictors of AIDS-related morbidity and mortality in a southern US cohort. AIDS Patient Care STDs 2007;21:681-690
61. Ironson G, O'Cleirigh C, Fletcher MA, Laurenceau JP, Balbin E, Klimas N, Schneiderman N, Solomon G. Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. Psychosom Med 2005;67:1013-1021
62. Antoni MH, Goldstein D, Ironson G, LaPerriere A, Fletcher MA, Schneiderman N. Coping responses to HIV-1 serostatus notification predict concurrent and prospective immunologic status. Clin Psychol Psychot 1995;2:234-248
63. Mulder CL, Antoni MH, Duivenvoorden HJ, Kauffmann RH, Goodkin K. Active confrontational coping predicts decreased clinical progression over a one-year period in HIV-infected homosexual men. J Psychosom Res 1995;39:957-965
64. Solano L, Costa M, Salvati S, Coda R, Aiuti F, Mezzaroma I, Bertini M. Psychosocial factors and clinical evolution in HIV-1 infection: a longitudinal study. J Psychosom Res 1993;37:39-51.
65. Solano L, Costa M, Temoshok L, Salvati S, Coda R, Aiuti F, Di Sora F, D'Offizi G, Figa-Talamanca L, Mezzaroma I, Montella F, Bertini M. An emotionally inexpressive (type C) coping style influences HIV disease progression at six and twelve month follow-ups. Psychol Health 2002; 17:641-655
66. Nyamathi A, Flaskerud J, Leake B, Chen S. Impoverished women at risk for AIDS: social support variables. J Psychosoc Nurs 1996;34:31-39
67. Sarna L, Van Servellen GL, Padilla G. Comparison of emotional distress in men with acquired immunodeficiency syndrome and in men with cancer. App Nurs Res 1996;9:209-212
68. Kelly B, Raphael B, Statham D. A comparison of the psychosocial aspects of AIDS and cancer-related bereavement. Int J Psychiatry Med 1996;26:35-49.
69. Leserman J, Petitto JM, Gu H, Gaynes BN, Barroso J, Golden RN, Perkins DO, Folds JD, Evans DL. Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psy-chol Med 2002;32:1059-1073
70. Leserman J, Jackson ED, Petitto JM, Golden RN, Silva SG, Perkins DO, Cai J, Folds JD, Evans DL. Progression to AIDS: the effects of stress, depressive symptoms and social support. Psychsom Med 1999;61:397-406.
71. Theorell T, Blomkvist V, Jonsson H, Schulman S, Berntorp E, Stigendal L. Social support and the development of immune function in human immunodeficiency virus infection. Psychosom Med 1995;57:32-36
72. Goodkin K, Feaster DJ, Tuttle R, Blaney NT, Kumar M, Baum MK, Shapshak P, Fletcher MA. Bereavement is associated with time-dependent decrements in cellular immune function in asymptomatic human immunodeficiency virus type 1-seropositive homosexual men. Clin Diagn Lab Immunol 1996;3:109-118
73. Power R, Koopman C, Volk J, Israelski D, Stone L, Chesney MA, Spiegel D. Social support, substance use and denial in relationship to antiretroviral medication adherence among HIV-infected persons. AIDS Patient Care STDS 2003;17:245-252
74. Needle RH, Coyle SL, Genser SG, Trotter RT II, editors. Social Networks, Drug Abuse, and HIV Transmission. Rockville, MD: National Institute on Drug Abuse, US Department of Health and Human Services: NIDA Monograph 1995;151:1-224.
75. Price RK, Cottler LB, Mager D, Murray KS. Injecting drug use, characteristics of significant others, and HIV-risk behaviors. In: Needle RH, Coyle SL, Genser SG, Trotter RT, editors. Social Networks, Drug Abuse, and HIV Transmission. Rockville, MD: National Institute on Drug Abuse, US Department of Health and Human Services: NIDA Monograph 1995;151:38-59.
76. Kraemer HC, Stice E, Kazdin A, Offord D, Kupfer D. How do risk factors work together? Mediators, moderators and independent, overlapping, and proxy risk factors. Am J Psychiatry 2001;158:848-856
77. Antoni MH, Carrico AW, Duran RE, Spitzer S, Penedo F, Ironson G, Fletcher MA, Klimas N, Scheiderman N. Randomized clinical trial of cognitive behavioral stress management on human immunodeficiency virus load in gay men treated with highly active antiretroviral therapy. Psychosom Med 2006;68:143-151
78. Timbo BB, Tollefoson L. Nutrition: a cofactor for HIV disease. J Am Diet Assoc 1994;94:1018-1022
79. Hurwitz BE, Klaus JR, Llabre MM, Gonzalez A, Lawrence PJ, Maher KJ, Greeson JM, Baum MK, Shor-Posner G, Skyler JS, Schneiderman N. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized control trial. Arch Int Med 2007;167:148-154
80. Wood E, Montaner JSG, Chan K, Tyndall MW, Schechter MT, Bangsberg D, O'Shaughnessy MV, Hogg RS. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS 2002;16:2065-2072